Argus Research
- Home
- PTGX
as of 03-06-2026 3:34pm EST
$92.39
+$0.98
+1.07%
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | NEWARK |
| Market Cap: | 5.2B | IPO Year: | 2016 |
| Target Price: | $100.17 | AVG Volume (30 days): | 489.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.05 | EPS Growth: | -148.46 |
| 52 Week Low/High: | $39.60 - $96.54 | Next Earning Date: | 06-01-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 711.26% | Revenue Growth (next year): | -50.75% |
| P/E Ratio: | -44.72 | Index: | N/A |
| Free Cash Flow: | 56.1M | FCF Growth: | -69.32% |
AI-Powered PTGX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 78.62%
78.62%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Protagonist Therapeutics Inc. (PTGX)
Waddill William D.
Sell
Director
PTGX Feb 6, 2026
Avg Cost/Share
$83.68
Shares
20,000
Total Value
$1,673,600.00
Owned After
7,825
SEC Form 4
PATEL DINESH V PH D
Sell
President and CEO
PTGX Jan 27, 2026
Avg Cost/Share
$83.19
Shares
4,068
Total Value
$338,416.92
Owned After
574,505
SEC Form 4
MOLINA ARTURO MD
Sell
Chief Medical Officer
PTGX Jan 27, 2026
Avg Cost/Share
$82.00
Shares
5,000
Total Value
$410,000.00
Owned After
84,115
SEC Form 4
PATEL DINESH V PH D
Sell
President and CEO
PTGX Jan 26, 2026
Avg Cost/Share
$84.03
Shares
24,890
Total Value
$2,091,470.25
Owned After
574,505
MOLINA ARTURO MD
Sell
Chief Medical Officer
PTGX Jan 26, 2026
Avg Cost/Share
$82.28
Shares
5,000
Total Value
$411,400.00
Owned After
84,115
SEC Form 4
PATEL DINESH V PH D
Sell
President and CEO
PTGX Jan 23, 2026
Avg Cost/Share
$84.59
Shares
19,315
Total Value
$1,633,855.85
Owned After
574,505
SEC Form 4
MOLINA ARTURO MD
Sell
Chief Medical Officer
PTGX Jan 23, 2026
Avg Cost/Share
$82.42
Shares
13,151
Total Value
$1,083,905.42
Owned After
84,115
SEC Form 4
PATEL DINESH V PH D
Sell
President and CEO
PTGX Jan 20, 2026
Avg Cost/Share
$82.48
Shares
34,438
Total Value
$2,840,446.24
Owned After
574,505
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Waddill William D. | PTGX | Director | Feb 6, 2026 | Sell | $83.68 | 20,000 | $1,673,600.00 | 7,825 | |
| Ali Asif | PTGX | Chief Financial Officer | Jan 27, 2026 | Sell | $83.13 | 46,203 | $3,841,037.42 | 60,320 | |
| PATEL DINESH V PH D | PTGX | President and CEO | Jan 27, 2026 | Sell | $83.19 | 4,068 | $338,416.92 | 574,505 | |
| MOLINA ARTURO MD | PTGX | Chief Medical Officer | Jan 27, 2026 | Sell | $82.00 | 5,000 | $410,000.00 | 84,115 | |
| PATEL DINESH V PH D | PTGX | President and CEO | Jan 26, 2026 | Sell | $84.03 | 24,890 | $2,091,470.25 | 574,505 | |
| MOLINA ARTURO MD | PTGX | Chief Medical Officer | Jan 26, 2026 | Sell | $82.28 | 5,000 | $411,400.00 | 84,115 | |
| PATEL DINESH V PH D | PTGX | President and CEO | Jan 23, 2026 | Sell | $84.59 | 19,315 | $1,633,855.85 | 574,505 | |
| MOLINA ARTURO MD | PTGX | Chief Medical Officer | Jan 23, 2026 | Sell | $82.42 | 13,151 | $1,083,905.42 | 84,115 | |
| Ali Asif | PTGX | Chief Financial Officer | Jan 20, 2026 | Sell | $82.48 | 8,588 | $708,338.24 | 60,320 | |
| PATEL DINESH V PH D | PTGX | President and CEO | Jan 20, 2026 | Sell | $82.48 | 34,438 | $2,840,446.24 | 574,505 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 25, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYFeb 25, 2026 · 100% conf.
AI Prediction BUY
1D
+0.71%
$87.72
5D
+6.62%
$92.86
20D
+12.95%
$98.38
Price: $87.10 Prob +5D: 100% AUC: 1.000
0001104659-26-019658
false 0001377121
0001377121
2026-02-25 2026-02-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 25, 2026
PROTAGONIST THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-37852
98-0505495
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
Protagonist Therapeutics, Inc.
7707 Gateway Blvd., Suite 140
Newark, California 94560-1160
(Address of principal executive offices, including zip code)
(510) 474-0170
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which
registered
Common Stock, par value $0.00001
PTGX
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
On February 25, 2026, Protagonist Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025. A copy of the press release titled “Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update” is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press release, dated February 25, 2026, titled “Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update.”
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
The information in this report, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Protagonist Therapeutics, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Protagonist Therapeutics, Inc.
Dated: February 25, 2026
By: /s/ Asif Ali
Asif Ali
Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 6, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 6, 2025
0001104659-25-107753
false 0001377121
0001377121
2025-11-06 2025-11-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 6, 2025
PROTAGONIST THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-37852
98-0505495
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
Protagonist Therapeutics, Inc.
7707 Gateway Blvd., Suite 140
Newark, California 94560-1160
(Address of principal executive offices, including zip code)
(510) 474-0170
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which
registered
Common Stock, par value $0.00001
PTGX
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
On November 6, 2025, Protagonist Therapeutics, Inc. reported its financial results for the quarter ended September 30, 2025. A copy of the press release titled “Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update” is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press release, dated November 6, 2025, titled “Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update.”
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
The information in this report, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Protagonist Therapeutics, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Protagonist Therapeutics, Inc.
Dated: November 6, 2025
By: /s/ Asif Ali
Asif Ali
Chief Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 6, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 6, 2025
0001104659-25-074719
false 0001377121
0001377121
2025-08-06 2025-08-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 6, 2025
PROTAGONIST THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-37852
98-0505495
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
Protagonist Therapeutics, Inc.
7707 Gateway Blvd., Suite 140
Newark, California 94560-1160
(Address of principal executive offices, including zip code)
(510) 474-0170
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which
registered
Common Stock, par value $0.00001
PTGX
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
On August 6, 2025, Protagonist Therapeutics, Inc. reported its financial results for the quarter ended June 30, 2025. A copy of the press release titled “Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update” is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press release, dated August 6, 2025, titled “Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update.”
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
The information in this report, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Protagonist Therapeutics, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Protagonist Therapeutics, Inc.
Dated: August 6, 2025
By: /s/ Asif Ali
Asif Ali
Chief Financial Officer
Latest Protagonist Therapeutics Inc. News
PTGX Breaking Stock News: Dive into PTGX Ticker-Specific Updates for Smart Investing
MT Newswires
Wedbush Raises Price Target on Protagonist Therapeutics to $100 From $86, Keeps Outperform Rating
📈
AI Sentiment
Highly Positive
8/10
MT Newswires
Takeda, Protagonist Say FDA Accepts New Drug Application for Potential Polycythemia Vera Treatment
➖
AI Sentiment
Neutral
5/10
Business Wire
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
📈
AI Sentiment
Highly Positive
9/10
Simply Wall St.
Why Protagonist Therapeutics (PTGX) Is Up 11.3% After Rusfertide NDA And Collaboration Shift
➖
AI Sentiment
Neutral
4/10
Compare PTGX vs Leading Stocks
See how PTGX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PTGX Protagonist Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.